Dep2 Protein Modulation for Faster Antidepressant Onset
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressants are inadequate in treating major depressive disorder, with high recurrence rates, slow onset of action, and significant side effects, limiting their effectiveness and safety for many patients, and there is a need for new pharmacological approaches that target alternative pathways beyond serotonin and norepinephrine.
Innovation Solution
The development of nucleic acid molecules, proteins, and vectors related to specific nucleotide and amino acid sequences, such as those found in SEQ ID NO:2 and SEQ ID NO:3, which are used to modify gene expression or identify genetic variants associated with depression, enabling novel therapeutic strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antidepressants (serotonin/norepinephrine-based medications) are used to treat major depressive disorder, then some patients achieve remission from depression, but the onset of action is delayed (weeks) and there is an increased risk of suicide during initial therapy
Solution Approach 1:
The patent segments the treatment approach by identifying multiple distinct pharmacological targets (CRH1 receptor, FKBP5, HPA axis components) rather than relying on a single neurotransmitter system. This allows for more targeted and potentially faster-acting interventions that address specific pathological mechanisms in different patient subgroups.
Solution Approach 2:
The patent enables preliminary identification of patient subgroups through genetic markers and biomarkers before treatment initiation. This allows for selecting patients who are most likely to respond to specific novel mechanisms, potentially avoiding the delayed and trial-and-error nature of current antidepressant therapy.
2Reliability
If current antidepressants are used to treat major depressive disorder, then remission is achieved in some patients, but recurrence rates are high (approximately 85% of patients will suffer another episode)
Solution Approach 1:
The patent incorporates biomarker monitoring and genetic profiling to provide feedback on treatment response and predict recurrence risk. This allows for adjusting treatment strategies based on individual patient responses and preventing recurrence before it occurs.
Solution Approach 2:
The patent targets fundamental physiological parameters (HPA axis function, CRH signaling, FKBP5 regulation) that underlying depression pathophysiology rather than just symptom management. By modifying these core parameters, the treatment aims to produce more durable remission and reduce recurrence.
3Reliability
If current antidepressants are used to treat major depressive disorder, then some patients experience symptom relief, but side effects lead to medication discontinuation and increased morbidity
Solution Approach 1:
The patent applies local quality by targeting specific molecular pathways and receptors (CRH1, FKBP5, HPA axis) rather than broadly affecting multiple neurotransmitter systems. This selective targeting aims to achieve therapeutic effects while minimizing off-target side effects that plague current antidepressants.
Solution Approach 2:
The patent uses genetic markers and biomarkers as intermediaries to identify patients who will respond to novel mechanisms and predict which current medications cause adverse effects. This allows for avoiding harmful drug-patient mismatches before they occur.
4Adaptability or versatility
If novel pharmacological approaches targeting alternative pathways are developed, then broader applicability and potentially faster onset may be achieved, but the complexity of demonstrating efficacy increases due to limited understanding of depression etiology
Solution Approach 1:
The patent identifies fundamental biological pathways (HPA axis, CRH signaling, FKBP5 regulation) that are universally dysregulated across different patient populations with depression. By targeting these universal mechanisms, the treatment aims to achieve broad applicability across diverse patient subgroups.
Solution Approach 2:
The patent uses genetic markers, biomarkers, and imaging markers as intermediaries to objectively measure treatment efficacy and understand disease mechanisms. These intermediaries provide quantifiable endpoints that simplify the demonstration of efficacy in novel treatment approaches.
Data Source
AI summary
The present invention relates to DEP2, as well as other proteins, and their uses in connection with the treatment of major depression or related disorders.